bioAffinity Technologies (BIAF) Depreciation & Amortization - Total (2022 - 2026)

bioAffinity Technologies has disclosed Depreciation & Amortization - Total across 5 years of filings, most recently posting $24408.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization - Total fell 44.23% year-over-year to $24408.0; the TTM figure through Mar 2026 stood at $151004.0 (down 9.73% YoY), while the FY2025 annual figure was $170359.0, up 4.94% from the prior year.
• Depreciation & Amortization - Total declined to $24408.0 in Q1 2026, from $37529.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization - Total for BIAF reached as high as $166284.0 in Q4 2023 and fell as low as $800.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization - Total is $40243.0 (2024), against an average of $41283.0.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization - Total soared 5536.88% — and 2024, when it plunged 74.26%.
• A 5-year view of Depreciation & Amortization - Total shows it stood at $7282.0 in 2022, then soared by 2183.49% to $166284.0 in 2023, then sank by 74.26% to $42806.0 in 2024, then declined by 12.33% to $37529.0 in 2025, then slumped by 34.96% to $24408.0 in 2026.
• According to Business Quant data, Depreciation & Amortization - Total over the past three periods registered $24408.0, $37529.0, and $44599.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.